Institute for Clinical Pharmacodynamics

The Institute for Clinical Pharmacodynamics (ICPD) is a private research organization based in Schenectady, New York, in the United States. It positions itself as a translational medicine group focused on antimicrobial drug development, integrating pharmacology, statistics, and clinical medicine to support pharmaceutical and biotechnology clients from preclinical laboratory work through to patient care. The organization describes its work as spanning "from benchtop to bedside," and states that it is the only translational medicine group that takes an antimicrobial from the laboratory all the way to the patient. ICPD operates its own in vitro and in vivo translational medicine laboratories, alongside computer hardware and drug assay facilities. Its scientific staff includes Pharm.D., Ph.D., and M.D. scientists, and the organization emphasizes that its work goes beyond statistical number-crunching by combining statistics with pharmacology and medicine. According to its website, nine out of ten new antibiotics in the last decade have been "touched" by ICPD, underscoring its role as a specialist partner in antibacterial research and development. ICPD's services center on pharmacokinetic-pharmacodynamic (PK-PD) analysis, which it promotes as essential to modern drug development. The organization publishes educational materials such as a white paper on de-risking antibiotic drug development with PK-PD, and its experts are invited to participate in government and company advisory panels. A notable example is Dr. Paul G. Ambrose, who presented the Antimicrobial Agents Lecture at the World Microbe Forum 2021. As a private, independent research institute, ICPD does not disclose a parent company or public listing. Its client base consists of pharmaceutical and biotechnology companies, as well as government bodies involved in antimicrobial development. The organization's singular focus on translational medicine for anti-infectives distinguishes it within the contract research and clinical pharmacology landscape.

The Institute for Clinical Pharmacodynamics (ICPD) is a private research organization located in Schenectady, New York, United States. Public information about its founding year and founders is not available in the supplied evidence. The organization has built its reputation as a specialist in translational medicine for antimicrobial drug development, combining laboratory science with clinical pharmacology. ICPD operates its own in vitro and in vivo translational medicine laboratories, as well as computer hardware and drug assay facilities. This infrastructure allows the organization to conduct studies and deliver results within timelines that it claims others cannot match. Its scientific team is composed of Pharm.D., Ph.D., and M.D. scientists who share a focus on translational medicine. The institute's core expertise is in pharmacokinetic-pharmacodynamic (PK-PD) analysis, which it applies to help pharmaceutical and biotechnology clients develop antibiotics and other anti-infective drugs. ICPD promotes PK-PD as essential to modern drug development and has published educational materials, including a white paper titled "De-Risking Antibiotic Drug Development with PK-PD." The organization states that nine out of ten new antibiotics in the last decade have been touched by its work, reflecting a significant role in the antibacterial research ecosystem. ICPD's experts are frequently invited to participate in government and company advisory panels. In 2021, Dr. Paul G. Ambrose presented the prestigious Antimicrobial Agents Lecture at the World Microbe Forum, highlighting the institute's thought leadership in the field. The organization continues to operate as an independent, private entity focused solely on translational medicine for anti-infectives.

• Dr. Paul G. Ambrose presents the Antimicrobial Agents Lecture at World Microbe Forum 2021

A specialized translational medicine group that integrates pharmacology, statistics, and medicine to de-risk antimicrobial drug development, claiming that nine out of ten new antibiotics in the last decade have been touched by its work.

• PK-PD analysis

  Pharmacokinetic-pharmacodynamic analysis for antimicrobial drug development.

• Translational medicine services

  Benchtop-to-bedside services integrating laboratory and clinical data.

• In vitro and in vivo laboratories

  Owned translational medicine laboratories for drug testing.

• White paper: De-Risking Antibiotic Drug Development with PK-PD

  Educational white paper on the importance of PK-PD in drug development.

• 2022.01.16

  Reported2022.01.17

  ICP DAS and Exosite partner on ExoWISE[3]ICP DAS与Exosite合作推出ExoWISEprnewswire.com

  ICP DAS announced ExoWISE, a solution created through a new partnership with Exosite, combining Exosite platform technologies with a native device connection from ICP DAS's WISE-5231 gateway.

Read more

1. 1ICPD | Institute for Clinical Pharmacodynamicsicpd.com
2. 2Institute for Clinical Pharmacodynamics (United States) - Wikidatawikidata.org
3. 3ICP DAS与Exosite合作推出ExoWISEprnewswire.com